Awake Prone Positioning for Severe Acute Chest Syndrome
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
Acute chest syndrome (ACS) is the leading cause of admission to intensive care and the leading cause of death in patients with sickle cell disease. Irrespective of the cause of ACS, there is an heterogeneity in pulmonary ventilation/perfusion ratios, leading to worsening of the disease.
Efficiency of awake prone positioning (APP) in acute respiratory failure (ARF) was particularly highlighted during the COVID-19 pandemic. Several physiological factors contribute to this benefit including an improvement in ventilatory drive and gas exchange.
The investigator hypothesize that APP could lead to clinical improvement in ACS in terms of oxygenation and ventilatory drive, by improving the heterogeneity of ventilation
Eligibility criteria
Qualifiers
Age >18 years
Major sickle cell anemia (SS, SC, Sβ)
Admission in intensive care unit for ACS
Registered in the French social insurance regime.
Disqualifiers
Pregnant or breastfeeding women
Immediate need for intubation
Impaired vigilance status (Glasgow scale score < 12)
Pneumothorax
Trial design
Treatments tested in this trial
- Awake prone positioning (APP)
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov